EXELON for Alzheimer's

Exelon.PNG
Exelon.PNG

EXELON for Alzheimer's

0.00

FDA approved the EXELON patch in 2007 based on evidence from two randomized trials. The trial comparing the patch, capsule and placebo included 892 people with mild-to-moderate Alzheimer’s Disease (average MMSE of 17) who were an average of 74 years old; about two thirds were women. Researchers randomly assigned participants to take the EXELON Patch, EXELON capsules, or a placebo (inactive sugar pill) for about 6 months. Get the DrugFactsBox to see what happened. 

Read about Consumer Reports' take on EXELON here.

Add To Cart